Esthesioneuroblastoma 

  • Author: Michael Somenek; Chief Editor: Jules E Harris, MD   more...
 
Updated: Jan 13, 2012
 

Background

Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare neoplasm originating from olfactory neuroepithelium. Approximately 1,000 cases have been identified since Berger and Luc described the first case in 1924.[1] Due to the rare and complex nature of ENB, multiple opinions exist regarding the etiology, optimal staging system, and treatment modalities. These tumors often display varying biologic activity ranging from indolent growth, with patient survival exceeding 20 years, to a highly aggressive neoplasm capable of rapid widespread metastasis, with survival limited to a few months.

Images of esthesioneuroblastomas are shown below.

Esthesioneuroblastoma. Coronal CT scan of the orbiEsthesioneuroblastoma. Coronal CT scan of the orbits and sinuses shows a large, enhancing, and expansile mass occupying the ethmoid air cells that is invading the cribriform plate and breaking through to the left anterior cranial fossa. Image courtesy of Michael Lev, MD. Esthesioneuroblastoma. A 39-year-old man presentedEsthesioneuroblastoma. A 39-year-old man presented with 1 month of decreased vision, left facial numbness, and swelling. Physical examination demonstrated left-sided exophthalmos and blindness. He had also lost his sense of smell. Contrast-enhanced T1-weighted MRI demonstrated a large lesion that originated in the paranasal sinuses and extended through the cribriform plate into the anterior cranial fossa. He underwent a bifrontal craniotomy for resection of this tumor.

The prognosis depends on the magnitude of the disease on initial diagnosis. It should be noted that precise histologic diagnosis is difficult because ENBs are often confused with other small round cell neoplasms of the nasal cavity. Despite the difficulties associated with the treatment of ENB, evolving treatment modalities, including surgery, radiation, and adjuvant chemotherapy, have contributed to the better management and increased survival of ENB patients. This article provides an updated summary of ENB, including ongoing research, current thought on pathophysiology, staging, and an update on new surgical techniques used to treat these tumors.[2]

Next

Pathophysiology

Esthesioneuroblastomas (ENBs) are undifferentiated tumors of neuroectodermal origin derived from the olfactory epithelium.[3] The tumor cells are mitotically active and are the precursor cells that develop into sustentacular and neuronal cells. Inconsistent histologic presentations initially led to controversy surrounding the exact histologic origin of ENBs, and this ambiguity can confound clinical and prognostic decisions. In essence, ENBs contain variable arrangements of their small cells. Additionally, there exists a variable presence (or absence) of true rosettes and neurofibrillary material.

To date, no certain genetic factor has been identified that can accurately assist in the diagnosis or predict prognosis. This is partially due to the ability to analyze cancer genomes on a whole genome basis. Recently, a tool called array comparative genomic hybridization was applied to the analysis of ENBs.[4] Although many alterations were identified in this study, chromosomal gains in 7q11 and 20q and deletions in 2q, 5q, 6p, 6q, and 18q have been confirmed by at least 2 other studies. Interestingly, 20q is a region that has been implicated in other cancers, including breast, ovarian, and squamous cell carcinoma. Still, further experimentation will be required to determine the role of these genomic regions in ENB.

The demonstration of human achaete-scute homologue (HASH1) gene expression, although still investigational, could become the diagnostic procedure of choice.[5] The HASH1 gene is involved in olfactory neuronal differentiation and is expressed in immature olfactory cells[6] ; therefore, it could be useful in distinguishing ENB from other poorly differentiated small blue cell tumors.

Previous
Next

Epidemiology

Frequency

United States

The incidence of esthesioneuroblastoma in the United States follows trends observed worldwide.

International

Based on the reports in the literature, approximately 1,200 cases of esthesioneuroblastoma (ENB) have been identified since 1924. Interestingly, 80% of these have been identified in the last 25 years. However, the current data set cannot distinguish between a rising incidence and better recognition of the disease. ENB has an estimated incidence of 4 cases per 10 million individuals and accounts for approximately 5% of all sinonasal tumors. Similar incidence rates have been obtained through epidemiologic studies performed in Denmark.[7] To our knowledge, no studies suggest a geographic deviation.

Race

Esthesioneuroblastoma (ENB) does not show a predilection toward any individual race. ENB does not show familial prevalence and has been reported in all races and on all continents.

Sex

Esthesioneuroblastoma (ENB) affects males and females with similar frequency.

Age

Esthesioneuroblastoma (ENB) occurs in a wide range of age groups (3-90 y). There exists a bimodal peak of occurrence in the third and sixth decades of life.

Previous
Proceed to Clinical Presentation
 
 
Contributor Information and Disclosures
Author

Michael Somenek  MD, Fellow Physician, Department of Otolaryngology, Facial Plastic and Reconstructive Surgery, University of Illinois, Chicago

Michael Somenek is a member of the following medical societies: Alpha Omega Alpha and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Nicholas C Shera, PhD  Freelance Medical/Scientific Writer

Disclosure: Nothing to disclose.

Guy J Petruzzelli, MD, PhD, MBA, FACS  The Charles Arthur Weaver Professor of Cancer Research, Professor and Senior Attending Physician, Director of Head, Neck, and Skull Base Surgery, Department of Otolaryngology, Rush University Medical Center

Guy J Petruzzelli, MD, PhD, MBA, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Association for the Advancement of Science, American Association of Clinical Anatomists, American College of Surgeons, American Medical Association, American Society for Head and Neck Surgery, American Society of Clinical Oncology, Chicago Medical Society, North American Skull Base Society, Society of Surgical Oncology, Society of University Otolaryngologists-Head and Neck Surgeons, and Southwest Oncology Group

Disclosure: Nothing to disclose.

Thomas C Origitano, MD, PhD, FACS  Professor and Chair, Department of Neurological Surgery, Medical Director, Neuroscience Service Line, Co-Director, Center for Cranial Base Surgery, Loyola University Medical Center

Thomas C Origitano, MD, PhD, FACS is a member of the following medical societies: American Association of Neurological Surgeons, American College of Surgeons, Congress of Neurological Surgeons, and North American Skull Base Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Robert C Shepard, MD, FACP  Associate Professor of Medicine in Hematology and Oncology at University of North Carolina at Chapel Hill; Vice President of Scientific Affairs, Therapeutic Expertise, Oncology, at PRA International

Robert C Shepard, MD, FACP is a member of the following medical societies: American Association for Cancer Research, American College of Physician Executives, American College of Physicians, American Federation for Clinical Research, American Federation for Medical Research, American Medical Association, American Medical Informatics Association, American Society of Hematology, Association of Clinical Research Professionals, Eastern Cooperative Oncology Group, European Society for Medical Oncology, Massachusetts Medical Society, and Society for Biological Therapy

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Rajalaxmi McKenna, MD, FACP  Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD  Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research

Disclosure: GlobeImmune Salary Consulting

References

  1. Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. Jul-Aug 1997;17(4A):2683-706. [Medline].

  2. Zhang M, Zhou L, Wang DH, Huang WT, Wang SY. Diagnosis and management of esthesioneuroblastoma. ORL J Otorhinolaryngol Relat Spec. 2010;72(2):113-8. [Medline].

  3. Wenig BM, Prasad ML, Dulguerov P. Neuroectodermal tumors. In: Barnes L, Eveson JW, Reichart P, and Sidransky D, WHO Classification of Tumors. 2005.

  4. Guled M, Myllykangas S, Frierson HF Jr, Mills SE, Knuutila S, Stelow EB. Array comparative genomic hybridization analysis of olfactory neuroblastoma. Mod Pathol. Jun 2008;21(6):770-8. [Medline].

  5. Mhawech P, Berczy M, Assaly M, Herrmann F, Bouzourene H, Allal AS, et al. Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract. Am J Clin Pathol. Jul 2004;122(1):100-5. [Medline]. [Full Text].

  6. Carney ME, O'Reilly RC, Sholevar B. Expression of the human Achaete-scute 1 gene in olfactory neuroblastoma (esthesioneuroblastoma). J Neurooncol. Oct 1995;26(1):35-43. [Medline].

  7. Theilgaard SA, Buchwald C, Ingeholm P. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol. Apr 2003;123(3):433-9. [Medline].

  8. Kane AJ, Sughrue ME, Rutkowski MJ, Aranda D, Mills SA, Buencamino R, et al. Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg. Aug 2010;113(2):340-51. [Medline].

  9. Magnavita N, Sacco A, Bevilacqua L, D'Alessandris T, Bosman C. Aesthesioneuroblastoma in a woodworker. Occup Med (Lond). May 2003;53(3):231-4. [Medline].

  10. Tseng J, Michel MA, Loehrl TA. Peripheral cysts: a distinguishing feature of esthesioneuroblastoma with intracranial extension. Ear Nose Throat J. Jun 2009;88(6):E14. [Medline].

  11. Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D, et al. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck. Apr 2006;28(4):305-12. [Medline].

  12. Min KW. Usefulness of electron microscopy in the diagnosis of "small" round cell tumors of the sinonasal region. Ultrastruct Pathol. Sep-Oct 1995;19(5):347-63. [Medline].

  13. Argani P, Perez-Ordonez B, Xiao H. Olfactory neuroblastoma is not related to the Ewing family of tumors: absence of EWS/FLI1 gene fusion and MIC2 expression. Am J Surg Pathol. Apr 1998;22(4):391-8. [Medline].

  14. Hyams VJ, Batsakis JG, Michaels L. Olfactory neuroblastoma. In: Tumors of the Upper Respiratory Tract and Ear, Atlas of Tumor Pathology. Vol 25. Washington DC: Armed Forces Institute Press; 1988:. 240-8.

  15. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. Mar 1976;37(3):1571-6. [Medline].

  16. Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. May 1993;32(5):706-14; discussion 714-5. [Medline].

  17. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. Aug 1992;102(8):843-9. [Medline].

  18. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. Nov 2001;2(11):683-90. [Medline].

  19. Fitzek MM, Thornton AF, Varvares M. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. May 15 2002;94(10):2623-34. [Medline].

  20. Nichols AC, Chan AW, Curry WT, Barker FG, Deschler DG, Lin DT. Esthesioneuroblastoma: the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. Skull Base. Sep 2008;18(5):327-37. [Medline]. [Full Text].

  21. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys. Feb 1 2009;73(2):424-32. [Medline].

  22. Sterzing F, Stoiber EM, Nill S, Bauer H, Huber P, Debus J, et al. Intensity Modulated Radiotherapy (IMRT) in the treatment of children and adolescents - a single institution's experience and a review of the literature. Radiat Oncol. Sep 23 2009;4(1):37. [Medline].

  23. Tselis N, Heyd R, Baghi M, Zamboglou N. Interstitial high-dose-rate-brachytherapy in advanced esthesioneuroblastoma. Laryngoscope. Nov 2008;118(11):2006-10. [Medline].

  24. Gupta S, Husain N, Sundar S. Esthesioneuroblastoma chemotherapy and radiotherapy for extensive disease: a case report. World J Surg Oncol. Oct 5 2011;9:118. [Medline]. [Full Text].

  25. Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg. Feb 2006;132(2):134-8. [Medline].

  26. McElroy EA Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery. May 1998;42(5):1023-7; discussion 1027-8. [Medline].

  27. Porter AB, Bernold DM, Giannini C, Foote RL, Link MJ, Olsen KD, et al. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol. Nov 2008;90(2):201-4. [Medline].

  28. Koka VN, Julieron M, Bourhis J. Aesthesioneuroblastoma. J Laryngol Otol. Jul 1998;112(7):628-33. [Medline].

  29. Mishima Y, Nagasaki E, Terui Y, Irie T, Takahashi S, Ito Y, et al. Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma. Cancer. Sep 15 2004;101(6):1437-44. [Medline]. [Full Text].

  30. Turano S, Mastroianni C, Manfredi C, Biamonte R, Ceniti S, Liguori V, et al. Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. J Neurooncol. May 2010;98(1):131-5. [Medline].

  31. Castelnuovo P, Bignami M, Delù G, Battaglia P, Bignardi M, Dallan I. Endonasal endoscopic resection and radiotherapy in olfactory neuroblastoma: our experience. Head Neck. Sep 2007;29(9):845-50. [Medline].

  32. Castelnuovo PG, Delù G, Sberze F, Pistochini A, Cambria C, Battaglia P, et al. Esthesioneuroblastoma: endonasal endoscopic treatment. Skull Base. Feb 2006;16(1):25-30. [Medline]. [Full Text].

  33. Folbe A, Herzallah I, Duvvuri U, Bublik M, Sargi Z, Snyderman CH, et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy. Jan-Feb 2009;23(1):91-4. [Medline].

  34. Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. Laryngoscope. Jul 2009;119(7):1412-6. [Medline].

  35. Zanation AM, Ferlito A, Rinaldo A, Gore MR, Lund VJ, McKinney KA, et al. When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. Eur Arch Otorhinolaryngol. Nov 2010;267(11):1667-71. [Medline]. [Full Text].

  36. Beitler JJ, Fass DE, Brenner HA, Huvos A, Harrison LB, Leibel SA, et al. Esthesioneuroblastoma: is there a role for elective neck treatment?. Head Neck. Jul-Aug 1991;13(4):321-6. [Medline].

  37. Rosenthal DI, Barker JL, El-Naggar AK. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. Dec 1 2004;101(11):2567-73.

  38. Bradley PJ, Jones NS, Robertson I. Diagnosis and management of esthsioneuroblastoma. Curr OPin Otolaryngol Head Neck Surg. 2003;11:112-118.

  39. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res. 1994;385:363-9. [Medline].

  40. Constantinidis J, Steinhart H, Koch M. Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000. Otolaryngol Head Neck Surg. May 2004;130(5):567-74.

  41. Devaney K, Wenig BM, Abbondanzo SL. Olfactory neuroblastoma and other round cell lesions of the sinonasal region. Mod Pathol. Jun 1996;9(6):658-63. [Medline].

  42. Dias FL, Sa GM, Lima RA. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg. Nov 2003;129(11):1186-92. [Medline].

  43. Dulguerov P, Allal AS. Nasal and paranasal sinus carcinoma: how can we continue to make progress?. Curr Opin Otolaryngol Head Neck Surg. Apr 2006;14(2):67-72.

  44. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. Dec 15 2001;92(12):3012-29. [Medline].

  45. Frierson HF Jr, Mills SE, Fechner RE. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol. Nov 1986;10(11):771-9. [Medline].

  46. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, et al. Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck. Jul 2005;27(7):575-84. [Medline].

  47. Lund VJ, Howard D, Wei W. Olfactory neuroblastoma: past, present, and future?. Laryngoscope. Mar 2003;113(3):502-7. [Medline].

  48. Perez-Ordonez B, Caruana SM, Huvos AG. Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. Hum Pathol. Aug 1998;29(8):826-32. [Medline].

  49. Silva EG, Butler J, MacKay B, et al. Neuroblastomas and neuroendocrine carcinomas of the nasal cavity. A proposed new classification. Cancer. 2006;50:2388-2405.

 
Previous
Next
 
Esthesioneuroblastoma. Coronal CT scan of the orbits and sinuses shows a large, enhancing, and expansile mass occupying the ethmoid air cells that is invading the cribriform plate and breaking through to the left anterior cranial fossa. Image courtesy of Michael Lev, MD.
Esthesioneuroblastoma. A 39-year-old man presented with 1 month of decreased vision, left facial numbness, and swelling. Physical examination demonstrated left-sided exophthalmos and blindness. He had also lost his sense of smell. Contrast-enhanced T1-weighted MRI demonstrated a large lesion that originated in the paranasal sinuses and extended through the cribriform plate into the anterior cranial fossa. He underwent a bifrontal craniotomy for resection of this tumor.
Table. Histopathologic Grading According to Hyams[14]
Grade Lobular Architecture Preservation Mitotic Index Nuclear Polymorphism Fibrillary Matrix Rosettes Necrosis
I+ZeroNoneProminentHW rosettesNone
II+LowLowPresentHW rosettesNone
III+/-ModerateModerateLowFW rosettesRare
IV+/-HighHighAbsentNoneFrequent
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.